KR20220028150A - 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 - Google Patents

항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Download PDF

Info

Publication number
KR20220028150A
KR20220028150A KR1020227005469A KR20227005469A KR20220028150A KR 20220028150 A KR20220028150 A KR 20220028150A KR 1020227005469 A KR1020227005469 A KR 1020227005469A KR 20227005469 A KR20227005469 A KR 20227005469A KR 20220028150 A KR20220028150 A KR 20220028150A
Authority
KR
South Korea
Prior art keywords
bdca2
seq
binding fragment
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227005469A
Other languages
English (en)
Korean (ko)
Inventor
마크 알. 에이치. 크렙스
데이빗 다이
샨타누 슐레
다니아 라바
데이빗 마르틴
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Priority to KR1020247007023A priority Critical patent/KR20240033168A/ko
Publication of KR20220028150A publication Critical patent/KR20220028150A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227005469A 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Ceased KR20220028150A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247007023A KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
KR1020187034043A KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034043A Division KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007023A Division KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Publications (1)

Publication Number Publication Date
KR20220028150A true KR20220028150A (ko) 2022-03-08

Family

ID=58672794

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227005469A Ceased KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020187034043A Active KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247007023A Ceased KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187034043A Active KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247007023A Ceased KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Country Status (16)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (3) JP7045327B2 (enExample)
KR (5) KR20220028150A (enExample)
CN (2) CN116850282A (enExample)
AU (2) AU2017258191B2 (enExample)
BR (1) BR112018072125A2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
NZ (2) NZ787392A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023017936A1 (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672981A4 (en) * 2017-08-22 2021-09-15 Biogen MA Inc. PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
EP4559485A3 (en) 2018-07-19 2025-08-06 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
IL303279A (en) 2020-12-03 2023-07-01 Biogen Ma Inc Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023017936A1 (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물

Also Published As

Publication number Publication date
IL262514B1 (en) 2025-08-01
CA3022116A1 (en) 2017-11-02
MA44763A (fr) 2019-03-06
KR20190002563A (ko) 2019-01-08
PH12018502278A1 (en) 2019-09-09
JP2019520316A (ja) 2019-07-18
KR20240159012A (ko) 2024-11-05
JP2024038308A (ja) 2024-03-19
US20250289895A1 (en) 2025-09-18
IL262514A (en) 2018-12-31
IL262514B2 (en) 2025-12-01
US20190284281A1 (en) 2019-09-19
KR102366547B1 (ko) 2022-02-23
NZ747504A (en) 2025-08-29
EP3448425A1 (en) 2019-03-06
WO2017189827A1 (en) 2017-11-02
MX2023008075A (es) 2023-07-18
JP7045327B2 (ja) 2022-03-31
NZ787392A (en) 2025-08-29
AU2017258191B2 (en) 2024-06-13
CN109475623A (zh) 2019-03-15
BR112018072125A2 (pt) 2019-03-19
JP2022084782A (ja) 2022-06-07
CN109475623B (zh) 2023-05-26
MX2025000037A (es) 2025-02-10
CN116850282A (zh) 2023-10-10
CO2018012506A2 (es) 2018-12-14
AU2017258191A1 (en) 2018-11-15
MX2018012945A (es) 2019-03-06
KR20240033168A (ko) 2024-03-12
EA201892443A1 (ru) 2019-04-30
IL321561A (en) 2025-08-01
KR20250088784A (ko) 2025-06-17
AU2024203240A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
KR102366547B1 (ko) 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
JP6949718B2 (ja) 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物
US20220056135A1 (en) Bifunctional anti-pd-1/sirpa molecule
KR20210030366A (ko) 항-pd-1 항체 및 이의 용도
EP4095158A1 (en) Pharmaceutical composition containing anti-btla antibody and use thereof
CN111808190A (zh) 结合pd-1的抗体
CN112804989A (zh) 抗fgfr2抗体制剂
AU2021272212A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
JP2025512032A (ja) Ｐｄ－１抗体を含有する安定した高濃度アルギニン製剤及びその使用方法
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
AU2018266324B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
AU2024282654A1 (en) Alpha4beta7 integrin antibody compositions and methods of use
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
EP4536280A2 (en) Anti-igf-1r antibody compositions
WO2025098341A1 (en) IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
JP2025512031A (ja) Ｐｄ－１抗体を含有する安定した高濃度塩化ナトリウム製剤及びその使用方法
HK40052955A (zh) 抗fgfr2抗体制剂
JP2022524814A (ja) 抗ｌｉｎｇｏ－１抗体を含む医薬組成物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220217

Application number text: 1020187034043

Filing date: 20181123

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220317

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230420

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20231004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20231004

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20230919